Results 171 to 180 of about 93,887 (308)

Clinical pharmacokinetics and pharmacodynamics of antimalarial combination therapy

, 2009
In the face of growing drug resistance, the World Health Organization (WHO) has issued recommendations strongly encouraging the use of combination therapies to combat uncomplicated malaria.
Friberg Hietala, Sofia
core  

A Physiologically Based Pharmacokinetic and Pharmacodynamic (PBPK/PD) Model of Dapagliflozin in Type 2 Diabetes Mellitus: The Effect of Dosing, Hepatorenal Impairment, and Food. [PDF]

Pharmaceutics
Nemitz N, Elias M, König M.
europepmc   +1 more source

A dose‐finding population pharmacokinetic/pharmacodynamic model of ginisortamab, an anti‐gremlin‐1 monoclonal antibody, in patients with solid tumours

British Journal of Clinical Pharmacology, EarlyView.
Aims Ginisortamab, a first‐in‐class human monoclonal antibody for the treatment of advanced solid tumours, binds to gremlin‐1 and restores bone morphogenetic protein signalling. We used pharmacokinetic/pharmacodynamic (PK/PD) modelling to characterize the relationship between ginisortamab dose and serum gremlin‐1 binding, using model‐based simulations ...
Yin Cheong Wong, Luisa Rojas Chavarro, Paul Jones, David Egging, Wanchana Ungphakorn, Marta Valle, Ivan Matthews   +6 more
wiley   +1 more source

Editorial: Pharmacodynamic and pharmacokinetic aspects of redox signaling in inflammation-associated damage and diseases. [PDF]

Front Physiol
Rashid M, Kanumuri SRR, Malik MY.
europepmc   +1 more source

Repeated intradermal lipopolysaccharide challenge responses in healthy volunteers: Implications for clinical pharmacology studies

British Journal of Clinical Pharmacology, EarlyView.
Aim Intradermal application of lipopolysaccharide (LPS), a Toll‐like receptor 4 agonist, induces a local inflammatory response and is used as a human challenge model to evaluate the pharmacodynamics of investigational medicinal products. While currently applied in a single, parallel‐group setting, alternative within‐subject designs involving repeated ...
Alexandra A. J. Sillé, Juliette A. van den Noort, Iva Lelios, Diana R. Pereira, Marzia A. Scelsi, Erica S. Klaassen, Philipp Schoenenberger, Naomi B. Klarenbeek, Pierre‐Eric Juif, Pascal Espie, Manon A. A. Jansen, Matthijs Moerland, Richard W. D. Welford   +12 more
wiley   +1 more source

New Personalized Medicine Model for Medication Management. [PDF]

J Pers Med
Alagiakrishnan K, Halverson T, Olivares DVF, Sadowski CA.   +3 more
europepmc   +1 more source

Precision medicine in paediatrics: Progress and priorities

British Journal of Clinical Pharmacology, EarlyView.
Precision medicine is revolutionizing personalized healthcare, advancing both diagnostics and therapeutics at an unprecedented pace. Reviewing the paediatric applications of pharmacometrics, pharmacogenomics and advanced therapy medicinal products highlights not only the relevance of these exciting innovations to frontline care but also the significant
Nicola Husain, Claire Booth, Joseph F. Standing, Charlotte I. S. Barker   +3 more
wiley   +1 more source

Optimization of pharmacotherapy in obesity: pharmacokinetics and pharmacodynamics aspects [PDF]

Introducere. Organizaţia Mondială a Sănătăţii a relatat că 40% adulţi sunt supraponderali, iar 13% obezi. Obezitatea induce modificări în parametrii fiziologici, care pot influenţa farmacocinetica (absorbţia, distribuţia, metabolismul, eliminarea) şi ...
Mihalachi-Anghel, Maria, Rakovskaia, Tatiana, Spinosu, Galina, Babcineţchi, Victoria   +3 more
core  

Correction to: An automated pipeline to generate initial estimates for population Pharmacokinetic base models. [PDF]

J Pharmacokinet Pharmacodyn
Huang Z, Fidler M, Lan M, Cheng IL, Kloprogge F, Standing JF.   +5 more
europepmc   +1 more source

A prospective series of acute rivaroxaban overdose, coagulopathy and bleeding complications (ATOM 11)

British Journal of Clinical Pharmacology, EarlyView.
Aim There is limited research describing rivaroxaban overdose. We aim to describe rivaroxaban overdose, coagulopathy and bleeding complications. Methods This is a prospective series of acute adult (>14 years) rivaroxaban overdose presentations >40 mg enrolled in the Australian Toxicology Monitoring study and presenting to three Australian clinical ...
Katherine Z. Isoardi, Angela L. Chiew, Keith Harris, Geoffrey K. Isbister   +3 more
wiley   +1 more source